BioWorld Asia

April 4, 2007

Gene Therapy Gains Boost With $690M Collaboration

LONDON - Big pharma has publicly embraced gene therapy for the first time, with the signing of a $690 million deal between Sanofi-Aventis SA and Oxford BioMedica plc for TroVax. (BioWorld International) Read More

CardioVascular Seeks AIM Status To Negate Naked Short Selling

New Enzyme Technology Could Solve Blood Supply Problems

Evotec Acquires Neuro3d Cash, Assets For $29.4M In Stock

EU Creating Registry To Boost Coordination Of Stem Cell Work

Advanced Therapies Rule Hits New EU Problems

MilleGen and LFB Partner On New Generation of MAbs

Pfizer Initiates Development Of NicOx Glaucoma Drug Candidate

Other News To Note

Nitec Pharma Gets $26M For Lodotra Development

Affibody Issues $28.5M In Shares To Boost New Diagnostic Tool

Today's news in brief

BioWorld

BioWorld briefs for June 11, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 9, 2026

3D rendering of β2-Adrenergic receptor GPCR protein molecule embedded in lipid bilayer membrane.

Skape Bio unlocks GPCR targets with de novo-designed miniproteins

BioWorld

Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...

New 5-HT2C receptor agonists reported in Hansoh patent

BioWorld Science

Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor...

Pre-disease plasma signature may help redefine lung cancer risk

BioWorld

Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...